Among axSpA patients enrolled in the BE MOBILE 1&2, those who received Bimekizumab achieved ASAS40 response earlier vs PBO Improvements in spinal pain and physical function were significantly reported as early as wk 1 in those who received BKZ vs PBO @RheumNow #ACR24 abs2363 https://t.co/JmcQdURTY4